# Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

> **NCT02592785** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 9 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BAY1163877

## Key facts

- **NCT ID:** NCT02592785
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-15
- **Primary completion:** 2017-02-05
- **Final completion:** 2017-12-06
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02592785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02592785, "Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02592785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*